The rate of non-osseous metastasis increased significantly by 2.8% per year from 2000 to 2011.
The 10-year overall survival rate was 94% for partial nephrectomy compared with 89.7% for radical nephrectomy in patients aged 20-44.
Relative survival rates for patients with advanced renal cell carcinoma have not improved significantly in the era of targeted agents.
Small case series shows benefit in patients with recurrent cancer in the prostate bed after radical prostatectomy.
Final overall survival data from a phase 3 trial reveal no significant difference between tivozanib and sorafenib.
Bladder cancer patients readmitted to the hospital within 30 days of surgery were 30% less likely to receive post-operative chemotherapy.
An maximal tumor diameter greater than 14 mm was associated with an eightfold increased risk of prostate cancer-specific mortality.
Risk of death is decreased by 37% in men receiving first-line docetaxel treatment.
Researchers speculate that patients opt for active treatment because of the influence of the diagnosing urologist.
Adjuvant radiotherapy after radical prostatectomy decreased the likelihood biochemical failure.
Compared with men younger than 50 years, men aged 75 and older had a nearly 9.4-fold increased risk of having high-risk disease, respectively.
The estimated rate of increase in upgrading was more than two times greater with intermediate-risk disease than low-risk disease at diagnosis.
It is associated with improved five-year overall and cancer-specific survival.
No adverse impact observed in men with high-risk disease.
SAN FRANCISCO—Everolimus is the first potential pharmacologic treatment option for patients with angiomyolipoma (AML), a benign tumor that usually occurs in the kidney, researchers reported at the 2012 Genitourinary Cancers Symposium.